KALA BIO, Inc. — Director's Dealing 2018

Feb 9, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2018-02-07

Reporting Person: Brazzell Romulus K (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-02-07	Stock Option (right to buy)	$12.86	A	70000	Acquired	2028-02-06	Common Stock (70000)	Direct

Footnotes

F1: This option was granted on February 7, 2018 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.